SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
- PMID: 33568663
- PMCID: PMC7876103
- DOI: 10.1038/s41467-021-21237-w
SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
Abstract
England has experienced a large outbreak of SARS-CoV-2, disproportionately affecting people from disadvantaged and ethnic minority communities. It is unclear how much of this excess is due to differences in exposure associated with structural inequalities. Here, we report from the REal-time Assessment of Community Transmission-2 (REACT-2) national study of over 100,000 people. After adjusting for test characteristics and re-weighting to the population, overall antibody prevalence is 6.0% (95% CI: 5.8-6.1). An estimated 3.4 million people had developed antibodies to SARS-CoV-2 by mid-July 2020. Prevalence is two- to three-fold higher among health and care workers compared with non-essential workers, and in people of Black or South Asian than white ethnicity, while age- and sex-specific infection fatality ratios are similar across ethnicities. Our results indicate that higher hospitalisation and mortality from COVID-19 in minority ethnic groups may reflect higher rates of infection rather than differential experience of disease or care.
Conflict of interest statement
The authors declare no competing interests.
Figures


References
-
- Office for National Statistics. Comparisons of All-cause Mortality between European Countries and Regions: January to June 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarri... (2020).
-
- Leon, D. A., Jarvis, C. I., Johnson, A. M., Smeeth, L. & Shkolnikov, V. M. What can trends in hospital deaths from COVID-19 tell us about the progress and peak of the pandemic? An analysis of death counts from England announced up to 25 April 2020. medRxiv10.1101/2020.04.21.20073049 (2020).
-
- Public Health England. Disparities in the Risk and Outcomes of COVID-19. https://assets.publishing.service.gov.uk/government/uploads/system/uploa... (2020).
Publication types
MeSH terms
Substances
Grants and funding
- MR/L01341X/1/MRC_/Medical Research Council/United Kingdom
- 200861/Z/16/Z/WT_/Wellcome Trust/United Kingdom
- UNS32973/WT_/Wellcome Trust/United Kingdom
- MR/M024903/1/MRC_/Medical Research Council/United Kingdom
- MC_PC_17114/MRC_/Medical Research Council/United Kingdom
- MR/R015600/1/MRC_/Medical Research Council/United Kingdom
- MR/S019669/1/MRC_/Medical Research Council/United Kingdom
- G0100811/MRC_/Medical Research Council/United Kingdom
- MR/K501013/1/MRC_/Medical Research Council/United Kingdom
- MC_PC_19012/MRC_/Medical Research Council/United Kingdom
- MR/N026934/1/MRC_/Medical Research Council/United Kingdom
- DH_/Department of Health/United Kingdom
- G0300665/MRC_/Medical Research Council/United Kingdom
- G9901399/MRC_/Medical Research Council/United Kingdom
- G9409531/MRC_/Medical Research Council/United Kingdom
- MR/J008761/1/MRC_/Medical Research Council/United Kingdom
- G0601966/MRC_/Medical Research Council/United Kingdom
- G0900897/MRC_/Medical Research Council/United Kingdom
- G9409634/MRC_/Medical Research Council/United Kingdom
- 200187/Z/15/Z/WT_/Wellcome Trust/United Kingdom
- 205456/Z/16/Z/WT_/Wellcome Trust/United Kingdom
- RE/18/4/34215/BHF_/British Heart Foundation/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous